The Michael J. Fox Foundation is preparing to launch the Parkinson’s Progression Markers Initiative (PPMI), a landmark five-year clinical study aiming to identify biomarkers of Parkinson’s disease progression. People recently diagnosed with PD are needed — and so are individuals who don’t have PD (or even a close relative with PD) to serve as controls.

	Biomarkers and PD Ken Marek, MD, principal investigator of PPMI, talks biomarkers with KQED’s Dave Iverson Download MP3 file - 6.5MB, 00.07.06 Click here to read the transcript			Q&A: Biomarkers Learn how biomarkers impact patients’ lives from diagnosis to drug development
	PPMI Press Release Read MJFF’s announcement of PPMI for an overview of the study.			Sign Up for Updates PPMI will launch this summer. Sign up to receive email updates as the study progresses.